Drug Trial Radar · NCT07841977
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Dec 2028
Study completion Jun 2034
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.
Conditions
- Primary Biliary Cholangitis
Interventions
SeladelparDrug
Capsule administered orally
PTM SeladelparDrug
Capsule administered orally
Cilofexor Dose BDrug
Tablet administered orally
PTM Cilofexor Dose ADrug
Tablet administered orally
PTM Cilofexor Dose BDrug
Tablet administered orally
Cilofexor Dose ADrug
Tablet administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Serum Concentration of Alkaline Phosphate (ALP) at Week 24Time frame: Baseline, Week 24
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to 30 days post last dose (up to 318 weeks)
- Percentage of Participants Experiencing Serious Adverse Events (SAEs)Time frame: First dose up to 30 days post last dose (up to 318 weeks)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Peak Gastroenterology Associates
Colorado Springs, Colorado · Recruiting
Florida Research Institute
Lakewood Rch, Florida · Recruiting
Digestive Healthcare of Georgia
Atlanta, Georgia · Recruiting
GI Associates of Northeast Tennessee
Johnson City, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.